Free Trial

Design Therapeutics Q4 2022 Earnings Report

Design Therapeutics logo
$5.99 -0.29 (-4.62%)
(As of 12/3/2024 ET)

Design Therapeutics EPS Results

Actual EPS
-$0.31
Consensus EPS
-$0.34
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Design Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Design Therapeutics Announcement Details

Quarter
Q4 2022
Time
N/A
Tim Sykes’ Urgent Trade Alert: “Make this move now” (Ad)

WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…

Click here to see a unique election-year trade

Design Therapeutics Earnings Headlines

The Biggest Financial Event of 2024?
Should you buy, sell, or hold your stock? To find the answer, let’s look at the actions of the world’s wealthiest investors… Right now, the world’s wealthiest investors are preparing for what could become ‘the biggest financial event’ of 2024.
RBC Capital Remains a Hold on Design Therapeutics (DSGN)
See More Design Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Design Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Design Therapeutics and other key companies, straight to your email.

About Design Therapeutics

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

View Design Therapeutics Profile

More Earnings Resources from MarketBeat